Overview

Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS

Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The objective of this study to evaluate the efficacy and safety of FG-4592 for the treatment of anemia in Chinese subjects with lower risk MDS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
FibroGen
Collaborator:
AstraZeneca